Population pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate PAGE 32 (2024) Abstr 10859 Peigné S, Pan Y, Friberg Hietala S, Mc Laughlin AM, Tajima N, Uema D, Zebger-Gong H, Tang Z, Zhou D, Garimella T, Abutarif M, Hong Y. ConferenceOncologyPharmacometricsTrial design and analysis Pharmetheus Affiliates Senior Director, MIDD Consultant Sophie Peigné See bio Principal Director, Client Operations Manager Sofia Friberg Hietala See bio Senior Director, MIDD Consultant Anna Mc Laughlin See bio
